Cargando…
PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report
Patients with chemo-refractory metastatic colorectal cancer (mCRC) have poor prognoses. The application of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors encouragingly improved the survival of mCRC patients with microsatellite instability-high (MSI-H)/mismat...
Autores principales: | Yang, Jiabao, Xing, Pengfei, Kong, Yuehong, Xu, Meiling, Zhang, Liyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176449/ https://www.ncbi.nlm.nih.gov/pubmed/37188188 http://dx.doi.org/10.3389/fonc.2023.1078915 |
Ejemplares similares
-
Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer
por: Lin, Haishan, et al.
Publicado: (2022) -
Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
por: Wang, Ting, et al.
Publicado: (2023) -
Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report
por: Liu, Yan, et al.
Publicado: (2023) -
Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer
por: Ding, Yuwei, et al.
Publicado: (2023) -
PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study
por: Kong, Yuehong, et al.
Publicado: (2022)